Last reviewed · How we verify
HS-10542 Low Dose
HS-10542 Low Dose is a small molecule Small molecule drug developed by Jiangsu Hansoh Pharmaceutical Co., Ltd.. It is currently in Phase 2 development for null.
HS-10542 Low Dose is a small molecule drug that targets the molecular target.
HS-10542 Low Dose is a small molecule drug that targets the molecular target. Used for null.
-
Baseline phase 2 → approval rate
+15.3pp
Industry-wide phase 2 drugs reach approval ~15.3% of the time (BIO/Informa 2023 industry benchmark across all therapeutic areas).
| Regulator | Country | Likely year | Lag vs FDA |
|---|---|---|---|
| FDA | US | 2031–2034 | — |
| EMA | EU | 2032–2035 | +0.7 yr |
| MHRA | GB | 2032–2035 | +0.7 yr |
| Health Canada | CA | 2032–2036 | +0.9 yr |
| TGA | AU | 2032–2036 | +1.2 yr |
| PMDA | JP | 2032–2036 | +1.5 yr |
| NMPA | CN | 2033–2037 | +2.3 yr |
| MFDS | KR | 2032–2036 | +1.4 yr |
| CDSCO | IN | 2032–2037 | +1.8 yr |
| ANVISA | BR | 2033–2037 | +2.3 yr |
Hover any row for the lag rationale. Lag estimates are reduced when the drug has FDA Breakthrough or EMA PRIME designation (sponsors file globally in parallel).
Estimate based on the BIO/Informa industry phase transition rates plus per-drug modifiers for therapeutic area, sponsor type, FDA designations, mechanism, and trial design. Per-jurisdiction lags from Tufts CSDD international approval studies. Not investment, clinical or regulatory advice. Methodology: /methodology#likelihood.
At a glance
| Generic name | HS-10542 Low Dose |
|---|---|
| Sponsor | Jiangsu Hansoh Pharmaceutical Co., Ltd. |
| Drug class | small molecule |
| Modality | Small molecule |
| Therapeutic area | null |
| Phase | Phase 2 |
Mechanism of action
The exact mechanism of action of HS-10542 Low Dose is not well understood, but it is believed to work by interacting with the molecular target, leading to a therapeutic effect.
Approved indications
- null
Common side effects
- null
Key clinical trials
- Efficacy and Safety Study of HS-10542 for IgA Nephropathy (PHASE2)
- Study of Safety and Efficacy of HS-10542 in Patients With Paroxysmal Nocturnal Hemoglobinuria (PHASE1, PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- HS-10542 Low Dose CI brief — competitive landscape report
- HS-10542 Low Dose updates RSS · CI watch RSS
- Jiangsu Hansoh Pharmaceutical Co., Ltd. portfolio CI
Frequently asked questions about HS-10542 Low Dose
What is HS-10542 Low Dose?
How does HS-10542 Low Dose work?
What is HS-10542 Low Dose used for?
Who makes HS-10542 Low Dose?
What drug class is HS-10542 Low Dose in?
What development phase is HS-10542 Low Dose in?
What are the side effects of HS-10542 Low Dose?
Related
- Drug class: All small molecule drugs
- Manufacturer: Jiangsu Hansoh Pharmaceutical Co., Ltd. — full pipeline
- Therapeutic area: All drugs in null
- Indication: Drugs for null
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing